NNNN
Anbio Biotechnology Class A Ordinary Shares
There isn't enough reported data to score NNNN yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
NNNN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Stable | |
| Strong |
NNNN's profitability and balance sheet are currently strong, and its cash flow is stable. There isn't enough data to rate its revenue.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NNNN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 26x | $3.80 | — |
| Cheap | 42x | $6.24 | +64% |
| Fair | 162x | $24.23 | +538% |
| Expensive | 420x | $63.06 | +1559% |
Historical ranges are pointers, not guarantees.
NNNN's PE is 26x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over NNNN in the historical PE scenario, which offers more potential upside but is not a forecast.
NNNN Forward outlook
There aren't enough analyst estimates for NNNN to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NNNN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.15 | +150% |
| Q4 2024 | $0.06 | -14% |
| Q4 2023 | $0.07 | -73% |
NNNN has the edge over OSCR in the latest year-over-year earnings comparison.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
NNNN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $8.6M | +5.6% |
| Q4 2024 | $8.2M | +107% |
| Q4 2023 | $4M | +39% |
| Q3 2023 | $1.8M | -36% |
| Q2 2023 | $3.3M | -63% |
| Q1 2023 | $1.5M | -83% |
NNNN has the stronger quarterly revenue trend. Revenue is up 162% for NNNN versus up 72% for OSCR.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 67% | +20 points |
| Q4 2024 | 24% | -22 points |
| Q4 2023 | 15% | +14 points |
| Q3 2023 | 15% | +14 points |
| Q2 2023 | 46% | -11 points |
| Q1 2023 | 46% | -11 points |
| Q4 2022 | 1.2% | N/A |
| Q3 2022 | 0.6% | N/A |
NNNN's operating margin was 67% last quarter, up 20 points from the same quarter a year ago, near the top of its range since 2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
NNNN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2023 | -$1.3M | -140% |
| Q3 2023 | -$616.6K | -137% |
| Q2 2023 | $2.3M | +324% |
| Q1 2023 | $1.1M | +96% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with NNNN at down 79%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
NNNN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +1.4M shares |
| 1 year | +3.3% | +1.4M shares |
NNNN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NNNN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -4.1x | Net Cash |
| Q2 2023 | -6.7x | Net Cash |
| Q4 2022 | -0.6x | Net Cash |
NNNN has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
NNNN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.4 | Neutral |
| Stochastic | 5.5 | Oversold |
NNNN's weekly RSI is 32 (neutral) and its Stochastic is 6 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NNNN PE vs Healthcare Sector
| Metric | NNNN | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | Same PE |
| PE % | 4 | 72 | 68 pts below |
NNNN is trading at 26x earnings, in line with the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over NNNN on valuation relative to its sector.
NNNN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.31 | 12% below |
| 20 week MA | $6.89 | 45% below |
| 50 week MA | $18.7 | 80% below |
OSCR has stronger trend alignment. NNNN is above 0 of 3 weekly averages versus OSCR above 5 of 5.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
NNNN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $5.77 | $33.5 | +481% |
| 2026 YTD | $33.5 | $3.80 | -89% |
NNNN has finished every year since 2025 higher, and it's down 89% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NNNN on returns for 2026, with the stronger performance.